Why Ginkgo Bioworks Holdings, Inc.’s (DNA) Stock Is Down 10.79%
As of Friday, October 30, Ginkgo Bioworks Holdings, Inc.’s DNA share price has dipped by 10.79%, which has investors questioning if this is right time to buy.Tudor Pop
Stock Evaluator: Ginkgo Bioworks Holdings, Inc. (DNA)
Ginkgo Bioworks Holdings, Inc. DNA
$11.21
-1.53
-12.01%
October 30, 2026 4:00:02 PM
EST
Volume: 2,729,332
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NYSE | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Ginkgo Bioworks Holdings, Inc.’s (DNA) Stock Is Up 7.54%
As of Wednesday, October 28, Ginkgo Bioworks Holdings, Inc.’s DNA share price has surged by 7.54%, which has investors questioning if this is right time to sell.Michael Rose
Why Ginkgo Bioworks Holdings, Inc.’s (DNA) Stock Is Up 6.94%
As of Tuesday, October 27, Ginkgo Bioworks Holdings, Inc.’s DNA share price has surged by 6.94%, which has investors questioning if this is right time to sell.Michael Rose
Why Ginkgo Bioworks Holdings, Inc.’s (DNA) Stock Is Down 6.38%
As of Friday, October 16, Ginkgo Bioworks Holdings, Inc.’s DNA share price has dipped by 6.38%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Ginkgo Bioworks Holdings, Inc.’s (DNA) Stock Is Down 12.07%
As of Friday, October 16, Ginkgo Bioworks Holdings, Inc.’s DNA share price has dipped by 12.07%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | DNA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $754.9 | $3,441.6 | 43% |
|
| Shares Out (Mil) | 62.1 | 105.4 | 53% |
|
| Institutional Ownership | 78.5% | 88.3% | 48% |
|
| Float (Mil) | 50.0 | 79.7 | 47% |
|
| Beta | 1.79 | 1.19 | 88% |
|
| Avg Daily Volume (000s) | 2,355 | 969 | 84% |
|
| Price Change (52-week) |
(8.0%) | 84.7% | 45% |
|
| Growth | DNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 17.3% | 7.6% | 77% |
|
| Net Income (5yr) | (19.8%) | (11.2%) | 20% |
|
| EPS (5yr) | (7.1%) | 2.5% | 24 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (15.0%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 1 | |
| Current EPS | ($0.540) | ($2.930) | ($2.900) | |
| Month Ago EPS | ($0.580) | ($3.200) | ($2.900) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | na | ($3.420) | ($3.210) | |
| Year/Year Chg | (41.5%) | (48.0%) | na | |
| Financials | DNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $132 | $800 | 29% |
|
| Net Income (TTM) (Mil) | ($291) | ($31) | 5% |
|
| EPS (TTM) | ($4.963) | ($0.300) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($170) | $47 | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($79) | $21 | 16% |
|
| Long-Term Debt (Q1) (Mil) | $404 | $284 | 56% |
|
| Enterprise Value (Q1) (Mil) | $542 | $3,582 | 35% |
|
| Valuation | DNA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.70 | 3.48 | 47% |
|
| P/E | na | 38.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 6.8 | na |
|
| Ratios | DNA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 68.0% | 47.7% | 79% |
|
| Net Margin | (219.6%) | (2.6%) | 4% |
|
| ROA | (26.2%) | (4.3%) | 18% |
|
| ROE | (56.3%) | (7.7%) | 14% |
|
| Liabilities to Assets | 57.5% | 41.8% | 51% |
|
| F-Score | 1 | 5 | 1% |
|
Passing Stock Screens
As of 10/30/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Lakonishok Screen
Factors: Value, Momentum
Identifying stocks trading at a discount to their industry norms but showing recent price strength and upward earnings revisions.
| Performance Since Inception: | 13.2% |
| +/- S&P 500: | +5.8 |
